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Abstract PrPC, the cellular isoform of the prion protein, serves to transduce the neurotoxic
effects of PrPSc, the infectious isoform, but how this occurs is mysterious. Here, using a
combination of electrophysiological, cellular, and biophysical techniques, we show that the flexible,
N-terminal domain of PrPC functions as a powerful toxicity-transducing effector whose activity is
tightly regulated in cis by the globular C-terminal domain. Ligands binding to the N-terminal
domain abolish the spontaneous ionic currents associated with neurotoxic mutants of PrP, and the
isolated N-terminal domain induces currents when expressed in the absence of the C-terminal
domain. Anti-PrP antibodies targeting epitopes in the C-terminal domain induce currents, and
cause degeneration of dendrites on murine hippocampal neurons, effects that entirely dependent
on the effector function of the N-terminus. NMR experiments demonstrate intramolecular docking
between N- and C-terminal domains of PrPC, revealing a novel auto-inhibitory mechanism that
regulates the functional activity of PrPC.
DOI: 10.7554/eLife.23473.001
Introduction
Prion diseases, or transmissible spongiform encephalopathies, comprise a group of fatal neurode-
generative disorders in humans and animals for which there are no effective treatments or cures.
These diseases are caused by refolding of the cellular prion protein (PrPC) into an infectious isoform
(PrPSc) that catalytically templates its abnormal conformation onto additional molecules of PrPC
(Prusiner, 1998). A similar, prion-like process may play a role in other neurodegenerative disorders,
such as Alzheimer’s and Parkinson’s diseases and tauopathies, which are due to protein misfolding
and aggregation (Jucker and Walker, 2013).
There is evidence that PrPC, in addition to serving as a precursor to PrPSc, acts as a signal trans-
ducer that mediates the neurotoxic effects of PrPSc (Biasini et al., 2012; Brandner et al., 1996;
Chesebro et al., 2005; Mallucci et al., 2003). Clues to possible mechanisms by which PrPC can initi-
ate neurotoxic activity have emerged from studies of transgenic mice expressing PrP molecules that
harbor certain internal deletions within the N-terminal domain. The PrPC molecule consists of a par-
tially unstructured N-terminal domain (residues 23–125), and a globular, C-terminal domain (residues
126–230) comprising three a-helices and two short, b-strands (Zahn et al., 2000). Deletions span-
ning a 21-amino acid region (amino acids 105–125) at the end of the flexible, N-terminal domain
induce a spontaneous neurodegenerative phenotype with certain similarities to natural prion
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diseases, but without accumulation of PrPSc (Baumann et al., 2007; Li et al., 2007; Shmerling et al.,
1998). Importantly, these phenotypes are dose-dependently suppressed by co-expression of wild-
type PrP, suggesting that the wild-type and deleted molecules interact with each other, or compete
for binding to a common molecular target that mediates both physiological and pathological effects.
The shortest deletion, D105–125 (designated DCR, for central region), produces the most severe
neurodegenerative phenotype, and requires the largest amount of wild-type PrP for rescue (Li et al.,
2007).
In our efforts to understand why these deleted forms of PrP are so neurotoxic, we have discov-
ered that they induce large, spontaneous ionic currents, recordable by patch clamping techniques,
when expressed in a variety of cell lines (Solomon et al., 2010, 2011) and in primary neurons
(Biasini et al., 2013). Remarkably, these currents are silenced by co-expression of wild-type PrP in
the same cells, paralleling the rescuing effects of wild-type PrP in transgenic mice expressing
deleted PrP. This observation suggests that the spontaneous ionic currents themselves, or some
closely associated phenomenon, play a role in the neurodegenerative phenotype of these mice.
In this study, we uncover novel mechanistic features of the toxicity-inducing activities of PrPC. We
show that ligands binding N-terminal domain of PrPC abolish DCR PrP-induced currents, as do muta-
tions of positively charged residues at the extreme N-terminus of this domain. Remarkably, expres-
sion of the isolated N-terminal domain in the absence of the C-terminal domain also induces
spontaneous currents, indicating that the N-terminal domain is capable of acting as an autonomous,
toxicity-determining effector. We also demonstrate that anti-PrP antibodies targeting epitopes in
the structured, C-terminal domain induce ionic currents in cultured cells expressing wild-type PrPC,
and cause degeneration of dendrites on hippocampal neurons. These results, taken together with
structural evidence from heteronuclear NMR experiments, suggest a molecular model for PrPC in
which the N-terminal domain acts as a neurotoxic effector whose activity is regulated by the C-termi-
nal domain. We speculate that this inter-domain regulatory interaction could play a role in the physi-
ological function of PrPC, and that disruption of this interaction could contribute to pathology in
neurodegenerative disorders. Our results also have important implications for the safety of anti-PrP
antibody therapies for prion and Alzheimer’s diseases.
eLife digest Prion diseases are a group of degenerative illnesses of the brain caused when a
molecule called the prion protein (PrP for short) adopts the wrong shape. These diseases include the
human form of mad cow disease, and are often fatal with no effective treatments or cures. Though
the normal activity of PrP is not certain, abnormal PrP can affect the healthy PrP on the surface of
brain cells and lead to disease. Similar mechanisms may also contribute to other life-threatening
brain disorders, including Alzheimer’s disease and Parkinson’s disease.
It had been shown that certain altered PrP proteins caused the death of brain cells by allowing
excessive electrical charges to cross the membranes of the cell. These changes led to symptoms in
animal models of the diseases. Experiments showed that adding a large amount of normal PrP to
the cells could prevent these effects. These studies, however, had not yet resolved how PrP behaves
inside cells and how this contributes to disease.
Using genetically modified mice and cells grown in the laboratory, Wu et al. investigated the role
of different parts of PrP in causing brain cells to degenerate. The experiments showed that one end
of the protein, called the N-terminus, is involved in the movement of electrical charges across the
cell membrane and is able to cause cell degeneration. By contrast, the other end of the protein, the
C-terminus, acts as a regulator for the N-terminus and can prevent cell degeneration. Further
investigation revealed that the C-terminus regulates the N-terminus through direct contact.
A better understanding of the role of PrP in prion diseases may help to reveal new treatments for
these and other degenerative brain disorders. In particular, the new findings highlight that
treatments should target the toxic N-terminus of altered PrP and not the regulatory C-terminus.
Further study will examine how different molecules in the brain control the interaction between the
two ends of PrP in healthy brain cells and how this is altered in diseased cells.
DOI: 10.7554/eLife.23473.002
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Results
N-terminal ligands, and reversal of positive charges, block DCR-induced
currents
Our previous studies identified a positively charged, nine amino acid segment at the very beginning
of the N-terminal domain (residues 23–31, KKRPKPGGW) that is essential for the current activity of
DCR PrP, and for the neurodegenerative phenotype of mice expressing another deletion mutant,
D32–134 (Solomon et al., 2011; Westergard et al., 2011b). As demonstrated in these earlier stud-
ies, deletion of residues 23–31 abolishes the spontaneous inward currents induced by DCR PrP (Fig-
ure 1—figure supplement 1A), as does addition of pentosan polysulfate (PPS), a negatively-
charged glycosaminoglycan which binds to several regions within the N-terminal domain (Figure 1—
figure supplement 1B). To probe further the role of the N-terminal domain in DCR PrP-induced cur-
rents, we tested the effect of additional ligands (antibodies and Cu2+ ions), as well alteration of posi-
tively charged residues within 23–31 region.
We tested two different anti-prion antibodies: 100B3 (Thuring et al., 2005), targeting residues
24–28, and POM11 (Polymenidou et al., 2008), which binds to the octapeptide repeats (residues
51–90). These antibodies (at concentrations of 57 nM and 33 nM, respectively), dramatically reduced
DCR PrP-induced currents (Figure 1A,B). As a control for POM11, we tested the effect of this anti-
body on DCR/D51–90 PrP, which retains current activity (Figure 1—figure supplement 1) as shown
previously (Solomon et al., 2011), but which lacks the octapeptide repeat region and would not be
expected to bind the antibody. As predicted, POM11 had relatively little effect on the currents
induced by DCR/D51–90 PrP (Figure 1B), while 100B3 and PPS were still inhibitory (Figure 1A, Fig-
ure 1—figure supplement 1B). These results demonstrate that antibody ligands targeting the
extreme N-terminus or the octapeptide repeats inhibit DCR PrP-induced currents. Interestingly, even
though the octapeptide repeats are not required for current activity, binding of an antibody ligand
to this region blocks the currents.
To further investigate the role of the octapeptide repeats, we tested the effect of Cu2+ ions,
which are known to bind to histidine residues located within four of the five octapeptide repeats and
at positions 95 and 110 (Millhauser, 2007). We found that treatment with Cu2+-pentaglycine (100
mM) blocked spontaneous currents in N2a cells expressing DCR PrP, but not in cells expressing DCR/
D51–90 (Figure 1C). Pentaglycine, with a Kd for Cu
2+ similar to that of PrPC (40 nM), was included as
a Cu2+ chelator in order to minimize the concentration of free Cu2+ (1 mM) while still allowing PrPC
to compete for Cu2+ ions. This result indicates that Cu2+ coordination to the octapeptide repeats
blocks DCR PrP currents.
Both PPS and copper have been shown to induce endocytosis of PrPC from cell surface
(Brown and Harris, 2003; Pauly and Harris, 1998; Shyng et al., 1995a). To determine whether
ligand binding to the N-terminus blocked DCR PrP-induced currents by reducing the amount of the
mutant protein on the cell surface, living cells were treated with PPS for 1 hr or Cu2+-pentaglycine
for 5 min in recording buffer at room temperature, and then surface-stained for DCR PrP with anti-
PrP antibody. Under these conditions, neither ligand altered the amount of DCR PrP on the cell sur-
face (Figure 1—figure supplement 2), presumably because of the short period of treatment and
the fact that the experiment was conducted at room temperature rather than 37˚C. As reported pre-
viously (Brown and Harris, 2003; Pauly and Harris, 1998; Shyng et al., 1995a), PPS did induce sig-
nificant endocytosis after treatment at 37˚C for 48 hr (Figure 1—figure supplement 2). Cells treated
with 100B3 or POM11 for 48 hr at 37˚C did not show any change in surface level of DCR PrP (Fig-
ure 1—figure supplement 2). Thus, the inhibitory effects of PPS, POM11, 100B3 and Cu2+ did not
result from acute changes in localization or trafficking of the mutant protein.
The extreme N-terminus of PrPC contains four positively charged amino acids (23KKRPKPGGW31).
To test the role of these residues in DCR-induced currents, we generated a variant of DCR (desig-
nated DCR/E3D) in which the three lysine residues (at positions 23, 24, and 27) were mutated to glu-
tamic acid and the single arginine residue (at position 25) was mutated to aspartic acid. We found
that N2a cells expressing this mutant did not show any currents (Figure 1—figure supplement 1).
This result indicates that the positive charges within the 23–31 segment are essential for DCR-
induced spontaneous currents.
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The N-terminal domain of PrPC induces ionic currents in the absence of
the C-terminal domain
Having shown that the N-terminal domain of PrPC is essential for DCR PrP-induced currents, we
wished to determine whether N-terminus is, by itself, sufficient to induce spontaneous currents. We
constructed a series of chimeric proteins (collectively designated PrP(N)-EGFP-GPI) consisting of var-
ious lengths of the N-terminal domain of PrPC (residues 23–109) fused to an EGFP molecule that was
equipped with the GPI addition signal from PrPC (Figure 2A). It was necessary to include the EGFP
moiety to enable efficient delivery of the protein to the cell surface (Heske et al., 2004); fusing the
N-terminal domain directly to the GPI addition signal results in a protein that is largely retained in
the ER and is degraded by the proteasome (Dametto et al., 2015). We confirmed cell surface
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Figure 1. Ligands binding to the N-terminal domain of PrPC block DCR-induced currents. (A) Left, representative
traces of currents recorded from N2a cells expressing DCR or DCR/D51–90 PrP in the absence (upper traces) or
presence (lower traces) of 100B3 (57 nM). Right, quantitation of the currents, plotted as the percentage of the total
time the cells exhibited inward current 200 pA (mean ± S.E.M., n = 10). (B) Left, representative traces of currents
recorded from N2a cells expressing DCR or DCR/D51–90 PrP in the absence (upper traces) or presence (lower
traces) of POM11 (33.3 nM). Right, quantitation of the currents (mean ± S.E.M., n = 10). (C) Left, representative
traces of currents recorded from N2a cells expressing DCR or DCR/D51–90 PrP in the absence (upper traces) or
presence (lower traces) of Cu-pentaglycine (100 mM). Right, quantitation of the currents (mean ± S.E.M., n = 10).
Scale bars in all panels: 1 nA, 30 s. *p<0.05; **p<0.01; ***p<0.005.
DOI: 10.7554/eLife.23473.003
The following source data and figure supplements are available for figure 1:
Source data 1. Quantification of DCR PrP-induced currents w/o treatment of ligands binding to PrPC N-terminus.
DOI: 10.7554/eLife.23473.004
Figure supplement 1. Mutated forms of PrP induce spontaneous currents.
DOI: 10.7554/eLife.23473.005
Figure supplement 2. Surface immunofluorescence staining of PrPC on N2a cells expressing DCR after treatment
with N-terminal ligands.
DOI: 10.7554/eLife.23473.006
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localization of the PrP(N)-EGFP-GPI constructs in transfected cells by fluorescence microscopy
(Figure 2B).
We found that cells expressing PrP(N)-EGFP-GPI constructs displayed spontaneous ionic currents.
The most active currents were observed with a construct encompassing PrP residues 1–109, with
successively lower current activities seen as the constructs became shorter (Figure 2C,D). Impor-
tantly, the PrP 32–109 construct was much less active, demonstrating the dependence of current
activity on the 23–31 region (Figure 2C,D). Expression of the C-terminal domain of PrPC (D23–89
PrP) did not induce any currents (Figure 2—figure supplement 1A).
We note that DCR/D51–90 PrP (Figure 1 and Figure 1—figure supplement 1) was more effective
at inducing currents than 1–31-EGFP or 1–59-EGFP (Figure 2). There are at least two possible rea-
sons for this observation. First, the DCR/D51–90 PrP construct contains additional sequences that
are not present in the 1–31-EGFP or 1–59-EGFP constructs. In particular, DCR/D51–90 PrP contains
residues 91–104, which are absent in 1–31-EGFP and 1–59-EGFP. These additional residues may
enhance production of spontaneous currents, consistent with the general observation that PrP-EGFP
chimeras incorporating longer stretches of the PrP N-terminus produced more currents (Figure 2C).
A second possible explanation is that the EGFP portion of the chimeric constructs may position the
PrP N-terminus at a different distance from the membrane, or in a different orientation, than the nat-
ural PrPC C-terminus, and this may diminish the ability of the N-terminus to interact with the mem-
brane to produce currents.
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Figure 2. The N-terminal domain of PrPC induces ionic currents in the absence of the C-terminal domain. (A)
Schematic of PrP(N)-EGFP-GPI constructs containing the N-terminus of PrP fused to EGFP and the PrP GPI
attachment sequence. The colored blocks represent the signal sequence (blue), polybasic residues 23–31 (yellow),
different portions of the N-terminus (grey), EGFP (green), and the GPI attachment sequence (magenta). (B)
Fluorescence image of N2a cells expressing PrP(1-109)-EGFP-GPI, showing localization of the protein on the cell
surface. Scale bar = 10 mm. (C) Left, representative traces of currents recorded from N2a cells expressing
constructs with different lengths of the N-terminus (1–31, 1–58, 1–90, 1–109 and 32–109). Scale bars: 500 pA, 30 s.
Right, quantitation of the currents, plotted as the percentage of the total time the cells exhibited inward
current 200 pA (mean ± S.E.M., n = 5 cells). *p<0.05; **p<0.01.
DOI: 10.7554/eLife.23473.007
The following source data and figure supplement are available for figure 2:
Source data 1. Quantification of N1-GFP-GPI-induced currents N2a cells.
DOI: 10.7554/eLife.23473.008
Figure supplement 1. Currents induced by PrP(1-109)-EGFP-GPI have the same features as currents induced by
DCR PrP.
DOI: 10.7554/eLife.23473.009
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The spontaneous currents associated with PrP(N)-EGFP-GPI had characteristics identical to the
currents associated with DCR PrP. First, PrP(N)-EGFP-GPI currents were sporadic in nature, and were
silenced by N-terminal ligands, including PPS, 100B3, POM11, and Cu2+-pentaglycine (Figure 2—
figure supplement 1B). Second, PrP(N)-EGFP-GPI currents, like DCR PrP currents, were silenced in a
dose-dependent fashion by co-expression of WT PrP (Figure 2—figure supplement 1C and D).
Moreover, removal of 23–31 region abolished the ability of WT PrPC to suppress both DCR and PrP
(N)-EGFP-GPI currents (Figure 2—figure supplement 1E and F), which is consistent with the obser-
vation that expression of D23–31 PrP does not rescue the neurodegenerative phenotype of mice
expressing D32–134 PrP (Turnbaugh et al., 2011). Finally, the currents induced by both DCR and
PrP(N)-EGFP-GPI were voltage-dependent, only being observed at holding potentials below  30
mV (Figure 2—figure supplement 1G and H).
NMR analysis reveals diminished interaction between the N- and
C-terminal domains of DCR PrP
The results presented thus far suggest that the C-terminal domain of PrPC may directly regulate the
N-terminal domain through a cis-interaction between the two domains. This interaction may be dis-
rupted by deletion of residues in the central region (as in DCR), or by substitution of an unrelated
protein for the C-terminal domain (as in PrP(N)-EGFP-GPI). Recently, Evans et al. (2016) used
1H-15N HSQC NMR to demonstrate that Cu2+ ions, when bound to the N-terminal, octapeptide
repeats, promote contact between these repeats and a C-terminal surface site encompassing helices
2 and 3. We predicted that this cis interaction would be weakened in DCR, thereby accounting for
the ability of the liberated N-terminal domain to induce spontaneous currents.
To test this prediction, we employed paramagnetic relaxation enhancement to probe the interac-
tion between octapeptide-bound Cu2+ ions and residues in the C-terminal domain. Using the meth-
ods of Evans et al. (2016), we compared the 1H-15N HSQC NMR spectra of recombinant, wild-type
mouse PrP (WT PrP) and DCR PrP in the presence and absence of one equivalent of Cu2+ (Figure 3—
figure supplement 1). Residues that come in close proximity to Cu2+ have their NMR cross-peaks
broadened, resulting in a lower observed intensity. For example, in the absence of Cu2+, a large
cross-peak shown in black corresponding to WT PrP residue E199 was observed (Figure 3—figure
supplement 1–A1). However, upon the addition of one equivalent of Cu2+ the corresponding cross-
peak depicted in red for residue E199 was greatly diminished in intensity. On the other hand, when
Cu2+ was titrated into DCR PrP, only a small shift between positions of the cross-peaks correspond-
ing to E199 was observed (Figure 3—figure supplement 1–A2). The chemical shift changes,
mapped onto the structure of WTPrP in Figure 3A,B, identify those residues in the C-terminal
domain affected by Cu2+ binding to the octapeptide repeats. In Figure 3A1 and A2, residues that
do not significantly change upon addition of Cu2+ are indicated by blue bars, while residues that
underwent a significant reduction in intensity are indicated by red bars. Cross-peaks that were not
identified are not shown in the figure. The large interaction patch seen in WT PrP is clearly reduced
in the DCR mutant (compare the residues highlighted in magenta in Figure 3B1/C1 and B2/C2),
especially in helices 2 and 3. These data suggest that deletion of residues in the central region dis-
rupts a Cu2+-driven regulatory interaction between the N- and C-terminal domains.
Antibodies against the C-terminal domain and hinge region of PrPC
induce ionic currents
Previous studies have reported that antibodies targeting specific epitopes in the structured domain
of PrPC cause neuronal death when administered in vivo or in brain slices (Reimann et al., 2016;
Solforosi et al., 2004; Sonati et al., 2013). We wondered whether the neurotoxicity of anti-PrP anti-
bodies might be due to their ability to induce ionic currents, similar to the way that DCR PrP causes
ionic currents in cultured cells (Solomon et al., 2010, 2011) and neuronal death in transgenic mice
(Li et al., 2007). We found that two antibodies targeting overlapping epitopes encompassing helix 1
in the C-terminal half of PrPC, POM1 (Polymenidou et al., 2008; Sonati et al., 2013) and D18
(Doolan and Colby, 2015; Williamson et al., 1998), induced spontaneous currents in N2a cells
expressing WT PrPC (Figure 4A).
A third anti-prion antibody with a similar epitope, ICSM-18 (Antonyuk et al., 2009), had a com-
parable effect, which was blocked by PPS and was absent with non-specific mouse IgG (Figure 4—
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figure supplement 1A). Because we were not able to obtain sufficient amounts of ICSM-18 for fur-
ther electrophysiological experiments, we turned to a single chain version of this antibody (ICSM-18
scFv). Like the holo-antibody, ICSM-18 scFv-induced spontaneous currents on on N2a cells overex-
pressing WT PrPC (Figure 4—figure supplement 1B), although higher concentrations were required
(200 nM for the scFv version, compared to 33.3 nM for the holo-antibody), presumably reflecting the
lower avidity of the monovalent scFv antibodies (Mammen, 1998). The spontaneous
currents induced by ICSM-18 scFv were abolished by PPS (100 mg/ml), and were absent with a con-
trol scFv (Figure 4—figure supplement 1B).
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Figure 3. DCR PrP shows diminished interaction between N- and C-terminal domains based on NMR analysis. (A) Reduction in peak intensities of
1H-15N HSQC spectra of WT PrP (A1) and DCR PrP (A2) in the presence of Cu2+. Data are shown only for the structured domain (residues 90–230). I/I0
values represent the ratios of peak heights in the presence and absence of 1 equivalent of Cu 2+. Residues with I/I0 values less than 1.0 SD below the
mean (dotted line) are shown in red, with unassigned residues omitted. (B) Residues (labeled and colored magenta) of WT PrP (B1) and DCR PrP (B2)
with I/I0values < 1.0 SD below the mean, mapped onto a ribbon representation of the NMR structure of mouse PrP(120-230) (PDB:1XYX). (C) Affected
residues (magenta) of WT PrP (C1) and DCR PrP (C2) are mapped onto surface plots of mouse PrP(120-230) (PDB:1XYX).
DOI: 10.7554/eLife.23473.010
The following figure supplement is available for figure 3:
Figure supplement 1. NMR signals for C-terminal residues broaden in the presence of Cu2+ bound to the N-terminal octarepeats.
DOI: 10.7554/eLife.23473.011
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Figure 4
Figure 4. Antibodies against the C-terminal domain induce ionic currents in N2a cells expressing wild-type PrPC.
(A) Left, representative traces of spontaneous currents recorded from cells expressing DCR PrP (top traces), and
currents induced by anti-prion antibodies (POM1 and D18) in cells expressing WT PrP (lower traces) in the absence
(left-hand traces) or presence (right-hand traces) of PPS (100 ug/ml). Right, quantitative analysis of the currents,
plotted as the percentage of the recording time the cells exhibited inward currents 200 pA. (mean ± S.E.M.,
n = 10). (B) Left, representative traces of currents recorded from cells expressing WT PrP in the presence of POM1,
POM11, or POM1+POM11. Right, quantitative analysis of the currents (mean ± S.E.M., n = 10). (C) Left,
representative traces of currents recorded from cells expressing WT PrP in the presence of D18, POM11, or D18
+POM11. Right, quantitative analysis of the currents (mean ± S.E.M., n = 10). (D) Left, representative traces of
currents induced by POM1 (upper traces) or D18 (lower traces) in cells expressing WT PrP (left-hand traces) or
D23–31 PrP (center traces), or in cells expressing WT PrP after pretreatment with PIPLC (1.0 units/ml for 4 hr at
37˚C) (right-hand traces). Right, quantitative analysis of the currents (mean ± S.E.M., n = 10). Scale bars in all
panels: 1 nA, 30 s. **p<0.01; ***p<0.005.
DOI: 10.7554/eLife.23473.012
The following source data and figure supplements are available for figure 4:
Source data 1. Quantification of anti-prion antibody-induced currents on N2a cells.
DOI: 10.7554/eLife.23473.013
Figure supplement 1. ICSM-18 induces currents in N2a cells.
DOI: 10.7554/eLife.23473.014
Figure supplement 2. Antibody-induced currents are dependent on PrPC expression level and are produced by
Fab fragments.
Figure 4 continued on next page
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The properties of the D18-, POM1-, and ICSM-18-induced currents were identical to those of the
spontaneous currents associated with DCR PrP, in terms of their sporadic nature, and suppression by
PPS (Figure 4A, Figure 4—figure supplement 1). In addition, treatment of WT PrP-expressing N2a
cells with POM11 blocked POM1- or D18-induced currents (Figure 4B and C), similar to the inhibi-
tory effect of POM11 on DCR PrP currents (Figure 1). Finally, cells expressing PrP with a deletion of
residues 23–31 were resistant to current induction by POM1 and D18 antibodies (Figure 4D), paral-
lel to the situation with DCR PrP, and emphasizing the importance of the polybasic region in anti-
body-induced current generation. One would expect a significant reduction in antibody-induced
currents in N2a cells expressing D23–31 PrP compared to cells over-expressing WT PrP (as observed
in Figure 4D), since the endogenous level of WT PrP in N2a cells is low, and we have shown that
untransfected cells display reduced currents after antibody treatment (Figure 4—figure supplement
2A). The fact that the D23–31-expressing cells do not display even low levels of current due to
endogenous PrPC may be due to some suppression of endogenous PrP expression, or perhaps com-
petition by the deleted protein for binding of the antibodies.
We performed several control experiments to demonstrate that the antibody-induced currents
were dependent on expression of cell-surface PrPC. First, we pretreated transfected N2a cells
expressing WT PrP with phosphatidylinositol-specific phospholipase C (PIPLC) at 1 U/ml for 4 hr at
37˚C, which cleaves the C-terminal GPI anchor and releases PrPC from the cell membrane. Neither
D18 nor POM1 induced currents in PIPLC pretreated cells (Figure 4D). Second, we demonstrated
that D18 did not induce currents in N2a cells in which PrP gene expression had been abolished by
CRISPR-Cas technology (Mehrabian et al., 2014) (Figure 4—figure supplement 2A). Finally, we
observed that D18 induced currents in untransfected N2a cells, although they were smaller than in
transfected N2a cells over-expressing WT PrPC, presumably due to the lower expression level of
PrPC in the former cells (Figure 4—figure supplement 2A). Taken together, these results indicate
that D18 and POM1-induced currents are PrP-dependent and are due to binding of the antibodies
to cell-surface PrPC.
To determine whether antibody-induced currents were the result of cross-linking of cell-surface
PrPC, or Fc-mediated antibody effector functions, we tested the effect of monovalent Fab fragments.
We found that Fab fragments prepared from D18-induced currents on N2a cells (Figure 4—figure
supplement 2B). This result, along with the effectiveness of ICSM-18 scFv antibody (Figure 4—fig-
ure supplement 1B), indicates that the ability of the C-terminally directed antibodies to induce cur-
rents in PrP-expressing cells is not due to cross-linking of cell-surface PrP by bivalent binding, or to
Fc-mediated effector functions such as complement fixation.
The antibody 6D11 (Pankiewicz et al., 2006), whose epitope (residues 93–109) encompasses sev-
eral positively charged residues following the octapeptide repeats, also induced currents in WT PrP-
expressing N2a cells (Figure 4—figure supplement 3). However, this antibody was less potent than
POM1 and D18, since the currents were much smaller, and higher concentrations were required to
produce consistent effects (66.7 nM for 6D11, compared to 33.3 nM for POM1 and 16.7 nM for
D18) (Figure 4—figure supplement 3 and Figure 4). 6D11 and three other antibodies targeting this
region, D13 (Williamson et al., 1998) (epitope: a.a. 95–105), POM3 (Polymenidou et al., 2008) (epi-
tope: a.a. 95–100) and ICSM-35 (Khalili-Shirazi et al., 2007) (epitope: a.a. 93–105), did not induce
currents at a concentration of 33.3 nM (Figure 4—figure supplement 3). Taken together, these
results indicate that antibodies targeting a positively charged segment at the terminus of the flexible
Figure 4 continued
DOI: 10.7554/eLife.23473.015
Figure supplement 3. 6D11, but not other central region antibodies, weakly induces currents in N2a cells.
DOI: 10.7554/eLife.23473.016
Figure supplement 4. POM1, but not antibodies recognizing other regions of the C-terminal domain, induces
currents.
DOI: 10.7554/eLife.23473.017
Figure supplement 5. D18 induces currents in Tga20 hippocampal neurons over-expressing WT PrP and in wild-
type neurons, but not in PrP knock-out (KO) neurons.
DOI: 10.7554/eLife.23473.018
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domain are less effective at inducing currents than antibodies binding to helix 1 in the C-terminal,
structured domain.
To explore further the epitope specificity of the antibody-induced currents, we tested two addi-
tional POM antibodies recognizing other epitopes in the C-terminal domain of PrPC. We found that
POM4 (whose epitope encompasses helix 3 and b1) and POM6 (which recognizes helices 1 and 2)
did not produce detectable currents when applied to WT PrP-expressing N2a cells at a concentra-
tion of 33.3 nM (Figure 4—figure supplement 4).
We tested whether anti-PrP antibodies induce currents in hippocampal neurons, as well as in N2a
cells. Treatment with D18 (33.3 nM) induced large, spontaneous inward in hippocampal neurons cul-
tured from Tga20 mice over-expressing wild-type PrP, and also increased the fragility of these neu-
rons (Figure 4—figure supplement 5). Eight of 10 Tga20 neurons analyzed in the presence of D18
were lost to observation shortly after breaking the patch, usually after recording an initial inward cur-
rent that did not return to baseline. This phenomenon is similar to what we previously observed in
cultured neurons expressing DCR PrP (Biasini et al., 2013), and may reflect a detrimental effect of
the induced currents on the integrity of the neuronal membrane. In contrast, recordings from Tga20
neurons in the presence of D18 and PPS remained stable for 5 min without current activity (Fig-
ure 4—figure supplement 5). Seven out of 15 wild-type neurons analyzed in the presence of D18
exhibited spontaneous currents, with no lost cells. D18 did not induce any currents in neurons from
Prnp /  mice, which lack PrP expression.
Antibodies recognizing the C-terminal domain of PrPC induce dendritic
degeneration in hippocampal neurons
Given the correlation between DCR PrP-induced currents and neurotoxicity, we hypothesized that
anti-PrP antibodies might have neurotoxic effects on cultured hippocampal neurons as a result of
the currents induced by these antibodies. To test this idea, we treated hippocampal neurons cul-
tured from Tga20 mice with D18 (16.7 nM) or POM1 (33.3 nM) for 48 hr, and then stained them with
an antibody to MAP2 to visualize changes in dendritic morphology. We observed that treatment
with D18 or POM1 caused dendrites to assume a characteristic ‘beaded’ appearance, which is typi-
cal of several kinds of toxic insults, including hypoxia and glutamate-induced excitotoxicity
(Hasbani et al., 2001) (Figure 5A). This effect was less in wild-type neurons and completely absent
in Prnp /  hippocampal neurons, indicating a dependence on the expression level of PrPC
(Figure 5A). Treatment of neurons with non-specific mouse IgG had no effect on dendritic morphol-
ogy (Figure 5A). Antibody 6D11, which weakly induced currents in WT PrP-over-expressing N2a
cells at 66.7 nM (Figure 4—figure supplement 3) induced mild dendrite degeneration in Tga20 neu-
rons (Figure 5—figure supplement 1A), while ICSM-35 at 33.3 nM, which did not induce currents,
did not cause dendritic degeneration (Figure 5—figure supplement 1B). Similarly, POM4 (33.3 nM)
and POM6 (33.3 nM) had no effect on dendritic morphology (Figure 5—figure supplement 2).
We tested whether antibody-induced dendritic changes, like currents, were dependent on the
N-terminal domain of PrPC. Supporting such a correlation, D18 had no effect on dendritic morphol-
ogy of hippocampal neurons cultured from mice expressing D23–31 or D23–111 PrP (Figure 6),
demonstrating that the N-terminal domain is essential for both the dendrotoxic and current-inducing
effects of the antibody. In addition, we found that co-treatment of neurons with the N-terminal
ligands PPS, 100B3, or POM11 abolished D18-induced dendritic degeneration (Figure 5B–D), analo-
gous to the way these ligands inhibit D18-induced currents (Figure 4A–C).
Given the proposed use of a humanized version of ICSM-18 as an immunotherapeutic for prion
and Alzheimer’s diseases in patients (Klyubin et al., 2014), we tested whether ICSM-18 induces den-
dritic toxicity. We observed that treatment of neurons cultured from Tga20 mice with ICSM-18 (6.67
nM) for 48 hr caused significant beading of dendrites, similar to the effects of POM1 and D18
(Figure 7A). At higher concentrations (33.3 nM), ICSM-18 caused significant loss of neuronal cell
bodies after 48 hr of treatment (not shown). In control experiments, no morphological effects were
observed with non-specific IgG (6.67 nM), or after treatment of neurons from Prnp /  mice with
ICSM-18 (Figure 7A). ICSM-18 scFv (200 nM) also induced dendritic degeneration on neurons cul-
tured from Tga20 mice but not Prnp /  mice, although the effect was milder than for the ICSM-18
holo-antibody (Figure 7B).
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Figure 5
Figure 5. Antibodies recognizing the C-terminal domain of PrPC induce dendritic degeneration in hippocampal neurons. (A) Top, representative
images showing dendrite morphology of cultured hippocampal neurons from Tga20 mice (which over-express WT PrPC), WT mice, or Prnp /  mice
after treatment for 48 hr with D18 (16.7 nM), POM1 (33.3 nM) or non-specific IgG (33.3 nM). The cells were stained with an antibody to MAP2 to visualize
dendrites. Boxed areas are enlarged below each image. Scale bar = 10 mm. Bottom, quantitation of dendritic degeneration, expressed as the length of
beaded dendrite segments as a percentage of total dendrite length, from 10 images in three independent cultures for each experimental condition.
Data represent mean ± S.E.M. **p<0.01; ***p<0.005. (B–D) Quantitation of dendritic beading following treatment with IgG, D18 alone, N-terminal
ligand (PPS, 100B3, or POM11) alone, or D18 together with the N-terminal ligand. Data represent mean ± S.E.M. ***p<0.005.
DOI: 10.7554/eLife.23473.019
The following source data and figure supplements are available for figure 5:
Source data 1. Quantification of dendritic degeneration, expressed as the length of beaded dendrite segments as a percentage of total dendrite length.
DOI: 10.7554/eLife.23473.020
Figure supplement 1. 6D11, but not ICSM35, has a weak effect on the dendritic morphology of Tga20 hippocampal neurons.
DOI: 10.7554/eLife.23473.021
Figure supplement 2. POM4 and POM6 have no effect on the dendritic morphology of Tga20 hippocampal neurons.
Figure 5 continued on next page
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Discussion
In this study, we have investigated two potentially interrelated functional activities of the PrPC mole-
cule: its ability to induce ionic currents, and its ability to cause degenerative changes in neurons.
Both activities are associated with deletions spanning the central region of the protein (residues
105–125), as well as with binding of antibodies to overlapping epitopes on the outer surface of helix
1 in the structured, C-terminal domain of the protein. Both activities are dependent on the flexible,
N-terminal domain of PrPC, and are blocked by deletion or mutation of this domain, or by binding of
specific ligands to the N-terminal domain. When fused to an unrelated protein (EGFP), the N-termi-
nal domain is sufficient by itself to induce current activity in the absence of the C-terminal domain.
Taken together with evidence from heteronuclear NMR experiments, these results suggest a molec-
ular model in which the N-terminal domain represents a toxic effector whose activity is regulated by
Figure 5 continued
DOI: 10.7554/eLife.23473.022
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Figure 6. D18 does not induce dendritic degeneration in hippocampal neurons cultured from D23–31 or D23–111
transgenic mice on the Prnp /  background. Representative images showing dendrite morphology of cultured
hippocampal neurons from mice expressing D23–31 PrP (upper panels) or D23–111 PrP (lower panels) after
treatment for 48 hr with D18 (16.7 nM) (left-hand panels) or non-specific IgG (16.7 nM) (right-hand panels). Neurons
were stained for an antibody to MAP2 to visualize dendrites. Scale bar: 20 mm.
DOI: 10.7554/eLife.23473.023
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the C-terminal domain, most likely by a Cu2+-promoted physical interaction between the two
domains. We speculate that alterations of this intramolecular regulation may have both pathological
and physiological consequences.
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Figure 7. Anti-prion antibody ICSM-18 induces dendritic degeneration in hippocampal neurons. (A) Left, representative images showing dendrite
morphology of cultured hippocampal neurons from Tga20 mice (which over-express WT PrPC) (left-hand panels) or Prnp /  mice (right-hand panels)
after treatment for 48 hr with non-specific IgG (6.67 nM) (upper panels) or ICSM-18 (6.67 nM) (lower panels). The cells were stained with an antibody to
MAP2 to visualize dendrites. Boxed areas are enlarged below each image. Scale bar = 10 mm. Right, quantitation of dendritic degeneration, expressed
as the length of beaded dendrite segments as a percentage of total dendrite length, from 10 images in three independent cultures for each
experimental condition. Data represent mean ± S.E.M. ***p<0.005. (B) Left, representative images showing dendrite morphology of cultured
hippocampal neurons from Tga20 mice (left-hand panels) or Prnp /  mice (right-hand panels) after treatment for 48 hr with control scFv (anti-
fluorescein, 200 nM) (upper panels) or ICSM-18 scFv (200 nM) (lower panels). The cells were stained with an antibody to MAP2 to visualize dendrites.
Boxed areas are enlarged below each image. Scale bar = 10 mm. Right, quantitation of dendritic degeneration, expressed as the length of beaded
dendrite segments as a percentage of total dendrite length, from 10 images in three independent cultures for each experimental condition. Data
represent mean ± S.E.M. ***p<0.005.
DOI: 10.7554/eLife.23473.024
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The N-terminal domain of PrPC is necessary and sufficient for current
activity
Our previous studies identified a nine amino-acid polybasic region at the N-terminus of PrPC (resi-
dues 23–31) that is essential for several toxic activities, including the spontaneous current activity
associated with the DCR PrP deletion mutant, the antibiotic hypersensitivity of cells expressing DCR
PrP, and the neurodegenerative phenotype of transgenic mice expressing the deletion mutant D34–
121 (Solomon et al., 2011; Westergard et al., 2011b). In the present study, we have shown that
reversal of positive charges within this region (three lysine residues and one arginine residue) abol-
ishes DCR current activity, as does treatment with ligands (antibodies, Cu2+ ions, pentosan sulfate)
that bind to this region or to other sites within the flexible N-terminal domain (residues 23–125).
Strikingly, the isolated N-terminal domain fused to an unrelated protein (EGFP) has the ability to
induce spontaneous ionic currents. The magnitude of these currents is quantitatively related to the
length of the N-terminus incorporated (fusions ending at residues 31, 58, 90, and 109 produce pro-
gressively more current), and the activity of these constructs is entirely dependent on the presence
of the 23–31 region. Taken together, these results suggest that the N-terminal domain of PrPC acts
as an autonomous effector of ionic current activity, and that basic amino acids at the extreme N-ter-
minus are essential for this activity.
We suggest two possible models to explain how the N-terminal domain induces currents. One
model is based on the fact that polybasic residues 23–31 resemble a ‘protein transduction domain’,
originally described in the HIV Tat protein (Wadia et al., 2008). Such positively charged domains are
capable of penetrating lipid bilayers and creating pores, by virtue of binding to and disrupting mem-
brane phospholipids (Herce and Garcia, 2007). The N-terminal domain of PrPC may thus function as
a ‘tethered’ protein transduction domain capable of spontaneously and transiently penetrating the
lipid bilayer to produce pores that allow passage of ions. Consistent with penetration of a
positively charged protein domain into or across the cell membrane, we find that the ionic current
activity associated with both DCR and PrP(N)-EGFP-GPI is apparent only at hyperpolarized holding
potentials (< 30 mV), similar to the resting potential of neurons ( 60 to  70 mV). A second possibil-
ity is that the N-terminal domain interacts with other membrane proteins, for example endogenous
ion channels or channel-modulating proteins, to induce current activity. Supporting this hypothesis is
our observation that co-expression of wild-type PrPC suppresses the ionic currents induced by DCR
and PrP(N)-EGFP-GPI, a phenomenon that could be attributable to competition between the wild-
type and mutant forms for a common membrane-associated target protein.
Antibodies to the C-terminal domain induce currents
Three different antibodies (POM1, D18, ICSM-18) targeting the C-terminal domain all induce ionic
current activity in cells expressing WT PrPC. Importantly, the properties of these currents are identi-
cal to those of the spontaneous currents associated with DCR PrP, in terms of their sporadic nature,
their blockage by N-terminal ligands (PPS, antibodies), and their absolute dependence on the pres-
ence of the polybasic 23–31 region. Based on crystal structures, mutagenesis studies, and peptide
arrays, the epitopes of these antibodies, while not identical, are largely overlapping and encompass
the outer surface of helix 1, as well as parts of the b1-a1 loop and helix 3 in the case of POM1
(Antonyuk et al., 2009; Doolan and Colby, 2015; Sonati et al., 2013). Three different antibodies
(POM3, D13 and ICSM-35) recognizing a basic region following the octapeptide repeats (residues
93–110) were ineffective at inducing currents, although a fourth one (6D11) had a weak effect at
high concentrations. Two other antibodies targeting additional epitopes in the C-terminal domain
had no effect. Table 1 summarizes the effects of the antibodies on current activity.
Together, these findings suggest a novel intramolecular regulatory mechanism controlling the
activity of PrPC (Figure 8A). Published crystal structures of both POM1 (Sonati et al., 2013) and
ICSM-18 (Antonyuk et al., 2009) bound to PrPC indicate that these antibodies do not induce major
structural alterations in the PrPC globular domain compared to the unliganded state, arguing against
antibody-induced allosteric changes as a toxic mechanism. Rather, our results suggest that antibod-
ies bound to helix 1 disrupt a critical regulatory interaction between the N- and C-terminal domains,
thereby liberating the N-terminal domain to produce toxic effects (Figure 8B). The fact both Fab
and scFv forms of the relevant antibodies display current-inducing activity suggests that antibody
ligands as small as 25–50 kDa are able to disrupt N-C interactions. We propose that a similar loss of
Wu et al. eLife 2017;6:e23473. DOI: 10.7554/eLife.23473 14 of 23
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regulation occurs when residues within the 95–125 region are deleted (as in DCR), or when an unre-
lated protein is substituted for the C-terminal domain (PrP(N)-EGFP-GPI) (Figure 8C,D). In this sce-
nario, the toxic activity of the liberated N-terminal domain would be blocked by binding of ligands,
including PPS, antibodies, or Cu2+ ions (Figure 8E).
The model proposed in Figure 8 is supported by biophysical evidence. NMR studies performed
here as well as previously (Evans et al., 2016; Spevacek et al., 2013) demonstrate that the N-termi-
nal domain docks onto the C-terminal domain, thereby regulating in cis the ability of the N-terminal
domain to promote toxic effector functions under normal conditions. Of note, the docking site
encompasses the POM1 epitope (Evans et al., 2016). Thus, binding of antibodies to this region
would be predicted to disrupt the N-C interaction, leading to toxic activity. We also show here that
deletion of the central region (in DCR PrP) weakens Cu2+-induced N-C interaction, consistent with
the hypothesis that the toxicity of the DCR mutant results from disrupted regulation of the N-termi-
nal domain. Cu2+ ions are physiological ligands of PrPC (Millhauser, 2007), and changes in endoge-
nous Cu2+ concentration are likely to modulate the strength of N-C interactions. Cu2+ binding to the
octarepeats may also directly suppress the toxic activity of the N-terminal domain, as we have
observed for the currents induced by DCR PrP and PrP(N)-EGFP-GPI.
C-terminally directed antibodies induce dendritic degeneration
In addition to acutely inducing ionic currents, helix 1 antibodies (POM1, D18, ICSM18) cause major
changes in dendritic morphology of cultured hippocampal neurons, in particular the appearance of
blebs or varicosities, when applied for longer periods of time (48 hr) (Table 1). These antibody-
induced dendritic changes are, like the currents induced by the same antibodies, entirely dependent
on the N-terminal domain of PrPC, and are blocked by N-terminal ligands and deletions of residues
23–31.
The parallel characteristics of the ionic currents and the dendritic changes induced by C-terminal
antibodies suggest a mechanistic connection between the two phenomena. One possibility is that
chronic activation of PrPC-mediated currents leads directly or indirectly to dendritic degeneration.
Consistent with this possibility, dendritic varicosities similar to those caused by anti-PrP antibodies
are a characteristic feature of glutamate excitotoxicity (Hasbani et al., 2001), and glutamate excito-
toxicity has been implicated in the neuronal degeneration induced by DCR PrP (Biasini et al., 2013;
Christensen et al., 2010). A second possibility is that current induction and dendritic degeneration
are parallel events that represent two distinct outputs of antibody binding to PrPC. For example, the
N-terminal domain of PrPC may stimulate currents by interacting with the lipid bilayer, and dendritic
changes by interacting with signal-transducing proteins embedded in the membrane.
Several other studies have reported toxic effects of anti-PrP antibodies, including several of the
ones used here, although some of these results have been contradictory. It has been reported that
antibodies D13 (Reimann et al., 2016; Solforosi et al., 2004), POM1 (Sonati et al., 2013), and
Table 1. Anti-prion antibodies used in this study, and their ability to induce ionic currents and den-
dritic toxicity.
Antibody Epitope Currents Dendritic toxicity
D18 (holo and Fab) 132–156 (a1) Yes Yes
POM1 138-147/204,8,12 (a1/a3) Yes Yes
ICSM18 (holo and scFv) 143–156 (a1) Yes Yes
6D11 93-109/97-100 Weak Weak
ICSM35 93–105 No No
D13 95–105 No No
POM4 121-134/218-21 (b1/a3) No No
POM6 140/145/174/177 (a1/ a2) No No
POM11* 51–90 (octarepeats) No No
*Blocks currents induced by D18 and POM1.
DOI: 10.7554/eLife.23473.025
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Figure 8. Models for the neurotoxic effects of PrP. (A) The C-terminal domain of PrPC negatively regulates the toxic effector function of the N-terminal
domain. +++, basic residues within the 23–31 region at the extreme N-terminus, which are essential for the toxic action of PrP. (B) Binding of
monoclonal antibodies to the C-terminal domain disrupts this regulatory interaction, releasing the N-terminal domain to produce toxic effects. (C)
Deletion of the central region, as in DCR PrP, produces a similar loss of regulation, with toxic consequences. (D) When EGFP is substituted for the
C-terminal domain of PrPC, regulation is also lost. (E) Binding of ligands (PPS, antibodies, Cu2+) to the N-terminal domain of DCR PrP blocks its ability
to exert toxic effects. These ligands would have a similar, inhibitory effect on PrP(N)-EGFP-GPI (not shown).
DOI: 10.7554/eLife.23473.026
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ICSM-18 (Reimann et al., 2016), but not D18 (Solforosi et al., 2004), caused acute death (within
24–48 hr) of neurons when injected stereotaxically into the hippocampus or cerebellum. Using a sim-
ilar protocol, however, Klo¨hn et al. (2012) found that D13 and ICSM-18 were non-toxic, as was
ICSM-35. Finally, Sonati et al. (2013) observed that chronic treatment (10–21 days) of cerebellar sli-
ces with several C-terminally directed antibodies, including POM1, caused neuronal death, and they
concluded that this effect was dependent on the flexible N-terminal domain. The results presented
here are consistent with this proposal.
It has been reported that anti-PrP antibodies trigger several toxic mechanisms in cerebellar slices,
including generation of reactive oxygen species, calpain activation and stimulation of the PERK arm
of the unfolded protein response (Sonati et al., 2013). Whether these pathways are operative in our
system remains to be determined. Since we observe relatively acute changes in dendritic morphol-
ogy without loss of neuronal viability, it is possible that the downstream toxic pathways engaged by
antibody treatment in our system may be different.
Implications
The results presented here have several important implications. First, they add to concerns that have
been raised regarding the use of anti-PrP antibodies as therapeutic tools for treatment of prion dis-
eases (White et al., 2003) and Alzheimer’s disease (Klyubin et al., 2014), given the potential side-
effects of these reagents on neuronal viability at nanomolar concentrations (Reimann et al., 2016;
Solforosi et al., 2004; Sonati et al., 2013).
Second, our results also suggest a mechanism by which pathologic ligands that bind to PrPC
could produce neurotoxic effects by disrupting the normal regulatory cis-interaction between the N-
and C-terminal domains, similar to the action of the antibodies described in this study. The Alz-
heimer’s Ab peptide, which binds to PrPC and triggers functional and structural alterations in synap-
tic transmission (Laure´n et al., 2009), is an example of such a ligand. PrPSc, which also binds to PrPC
(Solforosi et al., 2007), might act in a similar fashion, although the fact that mice expressing N-ter-
minally truncated PrPC remain susceptible to prion diseases (Supattapone et al., 2001;
Turnbaugh et al., 2012) argues against this as the primary pathogenic mechanism in these
disorders.
Finally, it is possible that the antibody-induced effects we have observed here are a reflection of
a physiological activity of PrPC. If so, natural ligands, including proteins, small molecules or metal
ions, may exist, whose binding to PrPC regulates an effector activity of the N-terminal domain, simi-
lar to the way that we suppose anti-PrP antibodies operate. Copper ions are examples of natural
ligands, binding of which to the octapeptide repeats promotes docking of the N- and C-terminal
domains (Evans et al., 2016; Spevacek et al., 2013). Endogenous ligands for the globular domain
may also exist, which either enhance or disrupt N-C interaction. Previous studies have implicated the
N-terminal domain of PrPC in several physiological activities of PrPC (Parkin et al., 2007; Pauly and
Harris, 1998; Sempou et al., 2016; Shyng et al., 1995b; Taylor et al., 2005; Watt et al., 2012),
some of which may be regulated by interaction with the C-terminal domain.
Materials and methods
Antibodies and other reagents
POM1, POM3, POM4, POM6 and POM11 antibodies (Polymenidou et al., 2008) were provided to
J.T. by the University of Zu¨rich, Institute of Neuropathology. Hybridomas producing the human-
mouse chimeric monoclonal antibodies D13 and D18 (Safar et al., 2002; Williamson et al., 1998)
were provided by Anthony Williamson, Dennis Burton, and Bruce Chesebro. Antibodies were affin-
ity-purified using protein A spin columns (Montage Antibody Purification Kit, EMD Millipore). Fab
fragments of D18 were prepared using the Pierce Fab preparation kit from Thermo Scientific. The
purity of all antibody preparations was verified by SDS-PAGE. The following antibodies were pur-
chased from commercial sources: 100B3 (Wagening UR, Netherlands); 6D11 (BioLegend, cat
#808001); ICSM-18 and ICSM-35 (D-Gen Ltd.).
Pentosan polysulfate (average MW = 4500–5000) was purchased from Biopharm Australia Pty
Ltd., and phosphatidylinositol-specific phospholipase C from Sigma (cat #P5542).
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Expression and purification scFv antibodies
The genes encoding the scFv form of ICSM18, constructed as described (Doolan and Colby, 2015),
and anti-fluorescein 4-4-20 scFv (negative control; obtained from Anne S. Robinson) were subcloned
into pHAGE-CMV-dsRed-UBC-GFP-W (Addgene plasmid #24526) in place of dsRed by restriction
digest cloning such that the final construct included an N-terminal Igk light chain secretion signal
and a C-terminal FLAG tag (DYKDDDDK) fused to the scFv, while maintaining the separate ORF
expressing GFP as a reporter. Lentivirus was generated by co-transfection of 5  105 HEK cells with
1.3 mg pHAGE expression vector, 1 mg psPax2, and 0.65 mg pMD2.G (Addgene plasmids #12260
and #12259) with TransIT-293 transfection regent (Mirus Bio LLC). After 72 hr, the supernatant was
filtered with a 0.45-mm syringe-tip filter and used directly for transduction.
CHO-S cells adapted to serum-free suspension culture (kindly provided by Kelvin H. Lee) were
grown in serum-free culture medium (Thermo Fisher Scientific, SH3054902) in vent-cap shake flasks
in a humidified incubator at 37˚C/5% CO2. Stable CHO cell lines were created by transducing 5 
105 CHO cells in 9 ml with 1 ml of HEK supernatant containing lentiviral particles in the presence 6
mg/ml polybrene (Sigma-Aldrich) for 2 days. Transduced cells were separated from non-transduced
cells based on GFP reporter expression by fluorescence-activated cell sorting (FACS) using a BD
FACSAria II FACS machine. Production of scFv was carried out by culturing the CHO lines for 7 days;
initial cultures contained 5  105 cells/ml. Supernatant was harvested by centrifugation and filtration
with a 0.22-mm syringe-tip filter before purification by anti-FLAG-affinity chromatography (Sigma-
Aldrich) and low-pH elution according to the manufacturer’s protocol. Eluted scFv was concentrated
and buffer-exchanged with a 10 kDa molecular weight cut-off centrifugal filter, assayed by silver
stain to ensure purity >90%, and quantified by Bradford assay. Purified scFv was stored in Tris-buff-
ered saline at 4˚C for short-term use, or  20˚C for long-term storage.
Plasmids
pcDNA3.1(+)Hygro plasmids (Invitrogen) encoding WT, DCR, DCR/D51–90, or D23–31 PrP have
been described previously (Solomon et al., 2010, 2011; Turnbaugh et al., 2011). PrP(N)-EGFP-GPI
constructs were created by fusing DNA sequences encoding residues 1–31, 1–58, 1–90, 1–109 or
32–109 of mouse PrP to residues 1–239 of EGFP, followed by a poly-glycine/serine linker (GGGGS)4
and then by residues 222–254 of mouse PrP in order to maintain GPI anchoring of the fusion protein.
The DCR/E3D plasmid encodes DCR PrP with the following mutations: K23E, K24E, R25D and K27E.
Cells
N2a cells (Cat. #: ATCC CCL-131, RRID: CVCL_0470) were maintained in DMEM supplemented with
nonessential amino acids, 10% fetal bovine serum and penicillin/streptomycin. The N2a cell line we
used in this study is mycoplasma free. Cells were transiently transfected using Lipofectamine 2000
with pEGFP-N1 (Clontech), along with empty pcDNA3.1(+)Hygro vector, or vector encoding WT or
mutant PrPs. Cell-surface expression of all PrP constructs was confirmed by immunofluorescence
staining.
Hippocampi from the newborn pups of the indicated genotypes were dissected and treated with
0.25% trypsin at 37˚C for 12 min (Shen et al., 2006). Cells were plated at a density of 65,000 cells/
cm2 on poly-D-lysine-coated coverslips in DMEM medium with 10% F12 and 10% FBS.
Mice
Prnp /  (Zurich I) mice (Bu¨eler et al., 1992) on the C57BL6 background, and Tga20 mice
(Fischer et al., 1996) have been described previously, and were obtained from EMMA (European
Mouse Mutant Archive). Tg(PrPD23–31) mice (Turnbaugh et al., 2011) and Tg(PrPD23–111) mice
(Westergard et al., 2011a) have been described previously, and were maintained on a Prnp-/- back-
ground. Wild-type C57BL6 mice were obtained from Charles River Laboratories.
Electrophysiological analysis
Recordings were made from N2a cells 24–48 hr after transfection. Transfected cells were recognized
by green fluorescence resulting from co-transfection with pEGFP-N1. Hippocampal neurons were
analyzed after 13–15 days in culture. Whole-cell patch clamp recordings were collected using stan-
dard techniques. Pipettes were pulled from borosilicate glass and polished to an open resistance of
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2–5 megaohms. Experiments were conducted at room temperature with the following solutions:
internal, 140 mM Cs-glucuronate, 5 mM CsCl, 4 mM MgATP, 1 mM Na2GTP, 10 mM EGTA, and 10
mM HEPES (pH 7.4 with CsOH); external, 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10
mM glucose, and 10 mM HEPES (pH 7.4 with NaOH). Current signals were collected from a Multi-
clamp 700B amplifier (Molecular Devices, Sunnyvale, CA), digitized with a Digidata 1440 interface
(Molecular Devices), and saved to disc for analysis with PClamp 10 software.
Localization of PrPC on N2a cells
Immunofluorescence staining of cell surface PrPC on N2a cells was performed by incubating livings
cells on ice with D18 antibody, fixing in 4% paraformaldehyde in PBS, and then labeling with Alexa
Fluor 594 goat anti-human IgG (Molecular Probes, Eugene, OR). Images of N2a cells were acquired
with a Zeiss LSM 710 confocal microscope.
Morphological analysis of hippocampal neurons
Neurons cultured for 14 days were fixed with 4% paraformaldehyde in PBS and permeabilized with
0.2% Triton100. Fixed cultures were then incubated with primary antibodies against microtubule-
activated protein 2 (MAP2; polyclonal; 1:1000; Abcam), followed by fluorescent secondary antibody.
Confocal microscopic analysis was performed on a Zeiss LSM 710 microscope using a 20X objective
lens. Identical acquisition settings were applied to all samples of the experiment. Images were ana-
lyzed with the NIH Image J program.
Preparation of recombinant PrP for NMR
Recombinant PrP constructs encoding wild-type mouse PrP(23-230) and mouse DCR PrP(D105–125)
in the pJ414 vector (DNA 2.0) were expressed in E. coli (BL21 (DE3) Invitrogen) (Evans et al., 2016).
Mutations were introduced using PCR-based, site-directed mutagenesis with mutagenic primers
(Invitrogen) and Phusion DNA Polymerase (Finnzymes). All constructs were confirmed by DNA
sequencing.
Bacteria were grown in M9 minimal media supplemented with 15NH4Cl (1 g/L) for
1H-15N HSQC
experiments or 15NH4Cl and
13C6-glucose (2.5 g/L) for 1H, 13C, 15N triple-resonance experiments
(Cambridge Isotopes). Cells were grown at 37˚C until reaching an optical density (OD) of 0.6, at
which point expression was induced with 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG). PrP
constructs were purified as previously described (Spevacek et al., 2013). Briefly, proteins were
extracted from inclusion bodies with 8 M guanidium chloride (GdnHCl) (pH 8) at room temperature
and were purified by Ni2+-immobilized metal-ion chromatography (IMAC). Proteins were eluted
from the IMAC column in 5 M GdnHCl (pH 4.5) and were brought to pH 8 with KOH and left at 4˚C
for 2 days to oxidize the native disulfide bond. Proteins were then desalted into 10 mM KOAc buffer
(pH 4.5) and purified by reverse-phase HPLC on a C4 column. The purity and identity of all con-
structs were verified by analytical HPLC and mass spectrometry (ESI-MS). Disulfide oxidation was
confirmed by reaction with N-ethylmaleimide and subsequent ESI-MS analysis.
Lyophilized protein samples were dissolved in degassed Milli-Q-purified H2O and allowed to fully
solubilize prior to all experiments. Protein concentrations were determined from the absorbance at
280 nm in GdnHCl buffer using an extinction coefficient of 64,840 M 1 cm 1 calculated for
mouse PrP(23-230) and 62,280 M 1cm-1 calculated for mouse DCR PrP(D105–125). For samples con-
taining Cu2+, the metal ion was added from stock solutions of Cu(OAc)2 or CuCl2 in H2O in which
the Cu2+ concentrations were accurately determined by EPR integration (Walter et al., 2006). Sam-
ples for NMR contained 200–400 mM PrP in 10 mM MES buffer (pH 6.1) with 10% D2O.
1H-15N HSQC NMR
NMR experiments were conducted on a Varian INOVA 600 MHz spectrometer equipped with a 1H,
13C, 15N triple-resonance cryoprobe. Resonance assignments were first obtained using standard tri-
ple-resonance experiments with a 400 mM samples of uniformly 13C,15N-labeled mouse PrP(23-230)
sample at 25˚C. Experiments included HNCO, HN(CA)CO, HNCACB, CBCA(CO)NH, and CC(CO)
NH. The assignments were then transferred to the 1H-15N HSQC spectrum at 300 mM and 37˚C by
following the cross-peaks through concentration and temperature titrations. Resonances were con-
firmed, and additional resonances were assigned by recording three-dimensional HNCACB and 15N-
Wu et al. eLife 2017;6:e23473. DOI: 10.7554/eLife.23473 19 of 23
Research article Neuroscience
NOESY-HSQC spectra at 300 mM and 37˚C. Finally, resonance assignments were transferred to the
1H,15N HSQC spectrum of MoPrP (H95Y/H110Y) at 300 mM and 37˚C by visual inspection. All NMR
spectra were processed with NMRPipe and NMRDraw (Delaglio et al., 1995), and analyzed using
Sparky NMR Analysis and CcpNmr Analysis (Vranken et al., 2005).
1H,15N HSQC spectra were recorded for MoPrP (H95Y/H110Y) and MoPrP(D105–125)H95Y con-
structs (300 mM) at 37˚C both in the absence of metal ions and in the presence of 300 mM CuCl2,
and the HSQC peak intensities were determined using Sparky NMR Analysis and CcpNmr Analysis.
Intensity ratios were analyzed using Kaleidagraph (Synergy Software) and residues with intensity
reductions greater the one standard deviation of the mean were considered significantly perturbed.
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